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There is an increasing body of evidence which suggests that IL-4 plays a role in the pathogenesis of TB, but a general
consensus on its role remains elusive. We have previously published data from a cohort of Ethiopian TB patients, their contacts,
and community controls suggesting that enhanced IL-4 production is associated with infection with M. tuberculosis, rather
than overt disease and that long-term protection in infected community controls is associated with co-production of the IL-4
antagonist IL-4d2, alongside elevated IL-4. Here, for the first time, we compare data on expression of IFN-c, IL-4 and IL-4d2 over
time in TB patients and their household contacts. During the follow-up period, the TB patients completed therapy and ceased
to display TB-like symptoms. This correlated with a decrease in the relative amount of IL-4 expressed. Over the same period,
the clinical status of some of their contacts also changed, with a number developing TB-like symptoms or clinically apparent
TB. IL-4 expression was disproportionately increased in this group. The findings support the hypothesis that elevated IL-4
production is generally associated with infection, but that TB disease is associated with a relatively increased expression of IL-4
compared to IFN-c and IL-4d2. However, the data also suggest that there are no clear-cut differences between groups: the
immune response over time appears to include changes in the expression of IFN-c, IL-4 and IL-4d2, and it is the relative, not
absolute levels of cytokine expression that are characteristic of clinical status.
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Ethiopian TB Patients and their Contacts Over Time. PLoS ONE 3(1): e1522. doi:10.1371/journal.pone.0001522
INTRODUCTION
Globally, tuberculosis (TB) is responsible for 2–3 million deaths
and over 8 million new cases annually [1], with the majority of
cases occurring in developing countries, especially in Sub-Saharan
Africa [2]. Lack of known correlates of protection to TB has
greatly hampered efforts for global control of the disease.
Untreated, smear-positive pulmonary TB (PTB) patients are the
main source of infection [3,4] and individuals living in the same
household or otherwise in frequent contact with an infectious
patient are therefore at a high risk of infection [5–7]. However, for
reasons as yet unexplained, the majority of these contacts contain
the infection without developing full-blown TB and it currently
impossible to predict who will and who will not, develop disease.
Likewise, while it is known that both TNF-a and IFN-c are
essential for controlling mycobacterial infections [8–11], the use of
either factor alone as a proxy marker for disease or immunity has
been unsatisfactory [12,13]. The consensus has thus become that
protection or susceptibility is a multi-factorial process, resting on
the balance of multiple factors. Assessing immune correlates
among close household contacts of infectious patients is therefore a
pressing issue, but relies on assessing different factors such as
exposure, infection, disease and/or protection from TB.
The basic hypothesis to be tested was that TB patients at
admission (particularly patients such as those recruited from
Butajira and Hossana hospitals in Southern Ethiopia, who
typically have quite advanced disease when they are first seen)
represented a ‘‘failed immune response’’ which might improve on
treatment, whereas infected, but healthy individuals represented a
‘‘protective immune response’’. Previous reports on this cohort
have suggested that elevated IL-4 mRNA expression in household
contacts correlates with heightened immune responsiveness to
ESAT-6–a good proxy for infection [14]. However, IL-4 mRNA
was also somewhat elevated in healthy, infected community
controls: the difference being that such individuals also expressed
elevated expression of mRNA for IL-4d2, an IL-4 antagonist and
IFN-c [15,16]. These specific cytokines were chosen since IFN-c
serves as a useful proxy for Th1 responses, as well as being
essential for immunity, while IL-4 is the prototypical Th2 cytokine
and has been associated with active TB. IL-4d2 (a splice variant of
IL-4 that appears to antagonize IL-4 action) was included because
its expression appears to correlate with protection from the
pathological effects of tuberculosis [14]–an effect that may be
shared with other IL-4 splice variants [17]. This approach has
previously been shown capable of identifying cytokine expression
profiles that correlate with either active or latent TB disease
[15,16,18] but the earlier studies were limited to comparing
responses between different clinical groups at a single time point
and could only hint at the evolution of the immune response
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changes occurred in these key cytokines over time. We collected
blood, and purified leukocytes from smear-positive TB patients or
their household contacts before the initiation of treatment of the
index case. A second sample was taken at the time the index case
successfully completed therapy. While there were few clear-cut
differences in individual cytokines between household contacts and
TB patients at entry to the study, healthy contacts had significantly
higher ratios of both IFN-c and IL-4d2 to IL-4 than TB patients.
Interestingly, as we compared the results in TB patients and the
contact group at entry and the end of the study, we saw quite
distinct trends, with an increased ratio of IL-4 to IFN-c or IL-4d2
in all cases being associated with a poorer clinical presentation and
a decreased ratio being associated with a better outcome.
Nonetheless, it is important to stress that similar underlying trends
were detectable in all of the household contacts, suggesting that
rather than protection or susceptibility being associated with the
development of strongly-polarized Th1/Th2 responses, that all the
TB-exposed individuals made a similar suite of responses (with both
‘‘Th1’’ and ‘‘Th2’’ components). The difference between contain-
ment of infection and progression to clinical TB therefore appear to
depend on successfully balancing the components of these responses.
MATERIALS AND METHODS
Study participants
Two separate cohorts, involving a total of 180 adults were
recruited from Hossana and Butajira Hospitals, 230 and 120 km,
respectively, southwest of Addis Ababa, Ethiopia. Of the study
participants, 76 were newly diagnosed, HIV-, smear-positive
pulmonary TB patients (TB) and 104 were close household
contacts, who had been living together with the index case for at
least 6 months prior to entry to the study. At entry to the study, the
contacts healthy (HHC) contacts who were sputum negative, HIV-
, asymptomatic and had normal chest X-rays. Blood samples were
obtained from all donors at entry to the study and again 6–
8 months later. There was one death among the participants in
this study (a TB patient), but the cause of death was not identified
so this individual was excluded from the analysis. One TB patient
failed therapy and was undergoing retreatment at the time of
followup–she also was not included in the analysis. However, not
all surviving participants could be located or were willing to
provide a second blood sample, and due to technical reasons, two
collections of blood samples were lost, so at 6–8 months of follow-
up, samples from approximately 46% of the original participants
were available for analysis-37 TB patients (TB) and 45 healthy
contacts (HHC). However, those from whom a second blood
sample could not obtained (or for whom the assays could not be
done) were still encouraged to attend the clinic for an examination,
and this group comprised another 16 TB patients and 33 healthy
contacts, for a total retention within the study of 73%. The median
age of all participants was 22 years (range 15–62), and 53% of
participants were male. Physicians at the hospitals performed a full
clinical examination of all participants, with chest X-ray and
sputum collection for smear and culture (where sputum could be
produced) as previously described [15,18]. There were no
significant differences in the composition of those who fully
participated in the followup visit and those who did not, with
regard to age, gender, physical condition, clinical diagnosis or
place of residence. TST results are not available, as the test is
regarded as unreliable in Ethiopia (where a substantial majority of
all adults are reactive [19]) and is neither recommended by local
health authorities nor routinely performed. All participants were
screened for HIV according to National Ministry of Health
guidelines with two rapid tests and confirmed with a further
ELISA at AHRI [14] and HIV-positive individuals were excluded
from the cohort. Pre- and post-test counseling was offered to all
participants and HIV positive individuals (n=2, both TB patients)
were referred to the Ethiopia Multi-Sectoral AIDS Program,
which provides care and ART. Only adults (15–60 years of age)
who had given written informed consent were included in the
study and this work was performed under a study protocol
approved by the Institutional and National Ethical Review
Committees (AHRI/ALERT and NERC).
Sampling
Blood samples (25 ml) were brought from the study sites to AHRI
laboratory at ambient temperature, in 50ml falcon tubes,
containing 2% sodium EDTA. Sputum samples were also
collected from the study participants for smear microscopy (with
Ziehl Neelsen) and culture, following the standard protocols.
RNA Extraction and RT-PCR
Unstimulated leukocytes were lysed immediately after blood
drawing with the RNEASY Blood RNA system (Quiagen,
Dusseldorf, Germany) according to the manufacturer’s instruc-
tions. The mRNA was transcribed into cDNA, using the
Omniscript reverse transcription kit (Quiagen, Dusseldorf, Ger-
many) with oligo dT primers, (according to the manufacturer’s
instructions), the concentration calculated from the optical density
using a GeneQuant spectrophotometer (Amersham Biosciences,
Amersham, UK) and stored at 220uC until use.
PCR amplification of cytokine mRNA
PCR was carried out in a total volume of 50 ml with 1 mg of cDNA
using the HotStarTaq Master Mix kit (Qiagen, Dusseldorf,
Germany) according to the manufacturer’s instructions. Primers
were designed to span introns so that amplification from genomic
DNA should not occur, and this was confirmed by comparing the
results from PCR of RNA preparations and the cDNA that was
prepared from it. A negative (no template) control was also
included in all PCR assays to test for contamination of reagents.
PCR products were visualized by running on 1% agarose
(Nusieve, FMC, Rockland, ME) gels containing SBYRgreen
(Molecular Probes, Eugene, OR) at 1:10,000 (5 ml in a 50 ml
gel) and normalized against the housekeeping gene, b-actin,
quantitated against standard curves using the same primers but
based on standardized samples containing known copy numbers of
cDNA, as previously described [20]. Our own work carried out
during this study suggests that b-actin is not an ideal housekeeping
gene [21]) but since the intention was to compare samples over
time (and the initial samples had been analyzed using b-actin), it
was retained throughout to ensure comparability. The PCR
conditions and primers used were designed for the project at
University College London (UCL) and the number of cycles was
optimized for each cytokine (IL-4, IL-4d2, IFN-c) as previously
described [15]. The fluorescence of bands in the gel under UV
transillumination was read using a 12-bit CCD camera (Sensicam,
UVP, San Gabriel, CA) and the data analyzed using the supplied
Labworks software.
Statistical analysis
The data obtained are presented as relative expression of the
target gene compared to the housekeeping gene b2actin and are
shown as medians6range when comparing groups. Comparison
of cytokine message levels between different groups was done using
one-way ANOVA (nonparametric, Kruskal-Wallis test), whereas
Th1/Th2 Balance Changes in TB
PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1522changes between baseline and follow-up results (change over time)
were analyzed by pairing individual results and then using a paired
T-test on the grouped data. A P-value#0.05 was considered
statistically significant in both cases.
RESULTS
Assessment of cytokine production at entry to the
study of different clinical cohorts using semi-
quantitative RT-PCR
Participants were recruited first when sputum-positive TB patients
presented at the local TB clinic. Once TB was diagnosed, the index
case was asked to return with their household members so that they
could also be examined-this is standard practice. If, after counselling
and explanation of the study’ aims, they were prepared to enter into
the study, the adult members of the household were enrolled. At
entry to the study, all participants received a clinical examination
and a blood draw. Cells from the peripheral blood of each group
were lysed (without in vitro culture) and mRNA extracted and reverse
transcribed into cDNA to analyse the ex vivo responses. This cDNA
was used for all subsequent analyses. We compared the expression of
IL-4, IFN-c,a n dI L - 4 d2 mRNA in healthy household contacts
(designated HHC, n=104) and index cases (designated TB, n=76).
As seen in Figure 1A, there were no significant differences between
these groups when individual cytokines were compared. This is
consistent with earlier results (author’s unpublished data and
[14,15]). However, there was a weak trend towards higher
expression of IL-4 in TB patients and when we compared the ratio
of IFN-c or the IL-4 antagonist IL-4d2 to IL-4, we saw a significant
difference between HHC and TB groups in both cases (Figure 1B).
These data suggest that there is a weak bias towards a more Th2-like
response in the TB patients compared to healthy contacts when
more than one cytokine is considered, but that the use of any single
marker is not very informative. This is perhaps not surprising,
considering the heterogeneous nature of the groups–the contacts
may include individuals in the early stages of TB, those making
protective immune responses as well as uninfected individuals–a
result confirmed by other analyses [14].
Assessment of changes in cytokine production over
time in different clinical cohorts using semi-
quantitative RT-PCR
We attempted to control for some of this variability by
investigating the cytokine responses in these groups 6–8 months
after entry to the study, by which time a better assessment of their
clinical prognosis could be made. At this stage, all the TB patients
but one had completed chemotherapy and had become asymp-
tomatic and culture negative, indicative of successful therapy. We
assessed cytokine production by PCR as before and as shown in
figure 2A, significant declines in mRNA for IL-4 and IL-4d2 were
seen, while IFN-c levels were essentially unchanged. The steep
decline in IL-4 mRNA contributed to a significant increase in both
the IFN-c/IL-4 and IL-4d2/IL-4 ratios, suggestive of a move
towards a more Th1-like response even though IL-4d2 mRNA
also declined somewhat (Figure 2B).
We performed a similar analysis of cytokine expression in the
household contact cohorts, but here the heterogeneous nature of
these groups became apparent. Where the inclusion criteria initially
designated contacts enrolled as Healthy (HHC–meaning no
symptoms or signs of TB) by 6–8 months after entry, some of the
contacts had begun to show TB-like symptoms (though they were
almost all sputum negative and only a few received a clinical
diagnosis of TB (one case of pulmonary TB, 2 cases of
extrapulmonary TB). As shown in Figure 3, when we compared
immune responses in the contacts who had remained asymptomatic
throughout the observation period, there was very little variation in
cytokine mRNA expression whether compared singly or as ratios.
However, when, we analyzed the data in the cohort who were
initially without symptoms but later developed TB-like symptoms
(n=10) a different pattern emerges, as shown in Figure 4.
Although the median expression of IFN-c and IL-4d2, increased
Figure 1. Comparison of relative levels of IL-4, IL-4d2 and IFN-c mRNA from unstimulated leukocytes of healthy household contacts (HHC,
n=104) and TB patients (TB, n=76). Results are presented as medians and ranges of either (A) cytokine message, assessed by RT-PCR, and
normalized against b-actin as a housekeeping gene or (B) the ratio of the normalized values of IL-4d2 and IFN-c divided by the normalized IL-4 value,
as a proxy for the Th1/Th2 balance. Levels of gene expression which were significantly different between groups are indicated, as are the associated p
values. Analysis of differences between the groups was performed by Kruskal-Wallis.
doi:10.1371/journal.pone.0001522.g001
Th1/Th2 Balance Changes in TB
PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1522Figure 2. Comparison of relative levels of cytokine mRNA from unstimulated leukocytes from TB patients (n=37) before and after treatment.
Results are presented as medians and ranges of either (A) cytokine message, assessed by RT-PCR, and normalized against b-actin as a housekeeping
gene or (B) the ratio of the normalized values of IL-4d2 and IFN-c divided by the normalized IL-4 value, as a proxy for the Th1/Th2 balance. Levels of
gene expression which were significantly different between groups are indicated, as are the associated p values. Analysis of differences within the
groups (over time) was performed by paired t-test.
doi:10.1371/journal.pone.0001522.g002
Figure 3. Comparison of relative levels of IL-4, IL-4d2 and IFN-c mRNA from unstimulated leukocytes of household contacts who remained
symptom-free during the study period (n=35). Results are presented as medians and ranges of either (A) cytokine message, assessed by RT-PCR,
and normalized against b-actin as a housekeeping gene or (B) the ratio of the normalized values of IL-4d2 and IFN-c divided by the normalized IL-4
value, as a proxy for the Th1/Th2 balance. Levels of gene expression which were significantly different between groups are indicated, as are the
associated p values. Analysis of differences between the groups was performed by Kruskal-Wallis, analysis of differences within the groups was
performed by paired t-test.
doi:10.1371/journal.pone.0001522.g003
Th1/Th2 Balance Changes in TB
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due to the very variable response, particularly for IL-4d2: while
some showed increased expression of IL-4d2, nearly half showed
the opposite trend. In contrast, all members of this cohort showed
an increase in IL-4 mRNA expression leading to a falling ratio of
IFN-c and IL-4d2 to IL-4 (Figures 4A and 4B).
This means that although the underlying trends for the ‘‘Th1’’
and ‘‘Th2’’ cytokines appear similar, when taken together, they
give quite different impressions: the ratio of these cytokines
to IL-4 increases in those becoming asymptomatic, and decreases
in those developing TB or TB-like symptoms. (Figures 2
and 4).
DISCUSSION
It is thought that one third of the world’s population is latently-
infected with M. tuberculosis, since only a small proportion of
antigen-responsive (and therefore, presumably infected) individu-
als develop full-blown clinical disease while the majority contain
the infection [22]. However, this is not a totally black and white
situation: it has been known for many decades that some of those
who remain apparently healthy may eventually reactivate their TB
infection, while some of those who eventually control the infection
may pass through a symptomatic phase. Experience from
European sanatoria tells us that even severe disease can persist
for years in the absence of chemotherapy–sometimes resolving,
more often not [23]. The reason for this differential susceptibility is
poorly understood and probably involves multiple innate as well as
acquired immune mechanisms. The study of immune responses in
M. tuberculosis-exposed and possibly infected individuals is therefore
essential in understanding the mechanisms at play.
A number of studies both from in vitro and in vivo experiments
and even from ex vivo studies have indicated the crucial role of
cytokines (particularly the pro-inflammatory cytokines IFN-c,
TNF-a, and IL-12) in TB [24–28]. Less information is available
on the role of other important mediators of immune function such
as IL-4, but what information there is suggests that elevated levels
of inflammation-modulating cytokines such as IL-4 and IL-10 are
associated with a poorer clinical outcome [29–32] or even
development of disease [33].
To address this problem, we looked at levels of the prototypical
Th1/Th2 cytokines IFN-c and IL-4, and the IL-4 antagonist, IL-
4d2 in TB patients and their close, household contacts, both at
entry to the study (when the index case was first identified) and at
the conclusion of treatment of the index case (6–8 months later).
In the recruitment area for the study (Southern Nations and
Nationalities Peoples Region or SNNPR), almost all admissions
are self-referred: thus TB patients are often gravely ill when first
seen at the clinic. Additionally, we screened their household
contacts and if they agreed to participate, enrolled those who
showed no signs of TB or TB-like disease. It should be noted that a
substantial proportion of household contacts (n=58 in this study,
or roughly 1/3) were excluded from this analysis because they had
already developed TB-like symptoms at the time they were first
seen. However, as they met neither the inclusion criteria for HHC
(not being healthy), nor for TB (not being sputum positive) they
could not be included in the study.
Our clinical studies in Ethiopia have relied on RT-PCR as an
adjunct to in vitro ELISA and ELISpot, because IL-4 has proven
difficult to detect as a protein, being both labile and present in very
low quantities [34]. In addition, current antibody pairs cannot
differentiate IL-4 and IL-4d2 ([35] and author’s unpublished data).
In these studies, plasma was analysed for cytokines by ELISA, but
as expected, IL-4 was detected in very few samples (data not
shown). There was, however, good correlation between protein
levels and mRNA expression for IFN-c [34].
In the present study, the level of individual cytokines was quite
variable and not significantly different, even between TB patients
and the healthy contacts (Figure 1). At first glance, this is different
from other studies where patients with active TB were shown to
have increased numbers of IL-4 secreting T cells [36–38], but
Figure 4. Comparison of relative levels of cytokine mRNA from unstimulated leukocytes of initially healthy household contacts who developed TB-
like symptoms during the study period (n=10). Results are presented as (A) medians and ranges of cytokine message, assessed by RT-PCR, and
normalized against b-actin as a housekeeping gene or (B) the ratio of the normalized values of IL-4d2 and IFN-c divided by the normalized IL-4 value, as a
proxy for the Th1/Th2 balance. Levels of gene expression which were significantly different between groups are indicated, as are the associated p values.
Analysis of differences between the groups was performed by Kruskal-Wallis, analysis of differences within the groups was performed by paired t-test.
doi:10.1371/journal.pone.0001522.g004
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countries and typically compare uninfected, non-endemic controls
with TB patients. It is therefore not unexpected that results from
TB-endemic regions where exposure to many pathogens, including
helminthes, is frequent [39] will be different-particularly when
examiningcontactswhooftenhaveweeks,ifnotmonths,ofexposure
to a sputum positive index case. And yet, these contacts are the very
people whom physicians are most likely to see when considering a
diagnosis of TB. As a result we have not used negative controls from
developed countries, but have instead assumed that members of a
single household will be similarly exposed to pathogens and
environmental factors, so that differences in the immune response
associated with clinical status (with regard to TB) are most likely
related to the TB infection or exposure.
Even taking this limitation into account, a role for IL-4 in the
Ethiopian setting is supported by the significant reduction of IL-4
mRNA seen among treated TB patients at follow-up, implying
that chemotherapy-induced cure of TB reduced IL-4 production
(Figures 2 and 3). This finding is matched by similar, recently
published results in treated TB patients from South Africa [40].
The interpretation is further supported by our previously-
published work, where TB patients were found to have higher
levels of IL-4 than healthy community controls from the same
region of Ethiopia [15] but not contacts, and more recent findings
that elevated expression of IL-4 among TB contacts in this area
correlates with the magnitude of their recognition of ESAT-6 (a
proxy marker for the severity of infection [14,18].
Even more interestingly, that contacts who developed symptoms
consistent with TB (persistent cough, haemoptysis, fever, X-ray
changes, etc) between the two visits showed a significant increase
in the expression of IL-4 mRNA between entry to the study and
follow-up, reaching a level equivalent to that seen in untreated TB
patients. This suggests that IL-4 expression correlates with some
degree to progress to disease (Figure 4). These different outcomes
contrast even more starkly when the ratios of cytokine expression
are compared–where the appearance of symptoms corresponds to
falling ratios of IFN-c and IL-4d2 to IL-4, while their
disappearance corresponds with the opposite trend. While our
inability to prove that all individuals with TB-like symptoms were
in fact TB patients means that the data here cannot be conclusive,
this assumption is supported by the fact that 3 of these individuals
had progressed to full-blown TB at the time of their second visit.
At the very least, these observations do support the hypothesis that
increased expression of IL-4 (especially compared to other
cytokines) in peripheral blood could serve as a surrogate marker
for TB-related disease, and that its reduction may be an indicator
of restoration of immune response following cure due to treatment.
In the present study, we also measured the message level of IFN-
c ex vivo and consistent with our earlier findings, showed that IFN-c
could not discriminate the different cohorts, as its level was
comparable in all the study groups [15]. The persistent expression
of high levels of mRNA for IFN-c is not unexpected, given the
proinflammatory nature of many surface molecules found on M.
tuberculosis (for a review, see [41]). Thus, while it is clearly essential
for protection from M. tuberculosis infection [42–44], the level of
total IFN-c alone appears to be of limited value in differentiating
between exposure, infection and disease, as reported in both
animal [45–47] and human studies [48,49].
However, cytokines do not act in a vacuum and when taken in
context, IFN-c expression can be informative. While it is common
practice to describe an immune response as ‘‘Th1’’ or ‘‘Th2’’, in
reality, few, if any, responses are completely polarized to one
extreme or the other. It is the balance of cytokines such as IFN-c
and IL-4 (and other modulators such as IL-4d2, IL-12, IL-23, etc)
that determines the outcome of the response. When we compare
the ratio of these ‘‘Th1-like’’ and ‘‘Th2-like’’ cytokines, the
association between a profile biased toward Th2-like cytokines and
clinical disease (or an opposite bias, with continued health)
becomes even more pronounced. Similar observations have been
made by other groups, showing that a lower IFN-c/IL-4 mRNA
ratio correlated with a more severe disease in TB patients and that
this ratio was higher among healthy control subjects [14,15,36,50].
A recent publication suggests that this may be in part due to
improved survival of the mRNA for IL-4 compared to its
antagonistic splice variant IL-4d2 in TB patients [38].
In general, the ex vivo cytokine mRNA expression patterns we
detected seemed to reflect the clinical status of the participants inthis
study. These observations thus suggest that the higher the IFN-c/IL-
4 mRNA and IL-4d2/IL-4 ratios, the more likely that M. tuberculosis
infection will be controlled in the individual. These ratios could
therefore serve as valuable markers for disease susceptibility or
resistance to TB. However, these patterns cannot be diagnostic of
disease or health on their own, particularly since a single
determination of cytokine mRNA level in peripheral blood at one
moment in time is not adequate by itself as a status marker. More
work is needed to establish reliable bounds for cytokine expression,
and to validate the assumption that the symptomatic contacts are in
fact showing early signs of TB. This work is ongoing.
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